• Company
    • Overview
    • Management Team
    • Board of Directors
    • Investors
    • Advisory Board
    • Message from BIO
  • Pipeline
    • Overview
    • GB-102 and GB-103
    • GB-201, GB-202 and GB-203 – Glaucoma Products
  • Science
    • Overview
    • Ocular Drug Delivery Technology
    • Primary Open-angle Glaucoma and Ocular Hypertension
    • Retinal Disease
    • Glaucoma
    • Partnerships
  • logo
  • Media
    • Press Releases
    • Events
    • Publications and Posters
  • Careers
  • Contact

Investors

  • Deerfield
  • Orbimed
  • Hatteras
  • Brown Advisory
  • Abell
Contents
  • Overview
  • Management Team
  • Board of Directors
  • Investors
  • Advisory Board
  • Message from BIO
Latest News
February 5, 2019

Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis

January 21, 2019

Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019

April 23, 2018

Graybug Vision Announces Presentations on Novel Treatments for Wet AMD and Glaucoma at ARVO 2018 Annual Meeting

To reduce the burden of treatment for patients with vision-threatening diseases through the development of injectable therapeutics that enable less frequent intervention and improve medical delivery for the physician.

Graybug Vision, Inc.
275 Shoreline Drive
Suite 450
Redwood City, CA 94065

info@graybug.com

Register for News Updates:

Subscribe to our company news email list and receive Graybug news as it is released. Your privacy is important, and your email address will be used only for this news distribution list.
Navigation
  • Home
  • Company
  • Pipeline
  • Science
  • Media
  • Careers
  • Contact

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok